2-AG — the ECS full agonist

TL;DR

• Brain concentration ~200× higher than anandamide.
• Full agonist at CB1 and CB2.
• Degraded by MAGL to arachidonic acid (prostaglandin precursor).
• MAGL inhibition raises 2-AG but also downstream prostaglandins.

2-AG and retrograde signalling

2-AG is made postsynaptically on Ca²⁺ rise, travels retrograde and activates presynaptic CB1 — the neuron dampens its own input. Explains DSI and DSE (Blankman 2007).

Physiological functions and therapeutic relevance

2-Arachidonoylglycerol plays a fundamental role in regulating inflammatory processes and cellular homeostasis throughout the human body. Since, unlike anandamide, it acts as a full agonist at both main receptors of the endocannabinoid system, it not only influences neuronal pathways but also controls essential functions of the immune system. The activation of CB2 receptors on immune cells by 2-AG dampens the release of pro-inflammatory cytokines. This makes the molecule a key player in research into therapeutic procedures for chronic inflammatory diseases and autoimmune processes in which the immune system overreacts.

Furthermore, scientific studies point to a pronounced neuroprotective effect of 2-AG. In traumatic brain injuries or strokes, a natural increase in the 2-AG concentration in the affected tissue is observed. This endogenous response presumably serves to cushion neuronal hyperexcitation and minimise subsequent cell death. The targeted pharmacological manipulation of 2-AG degradation therefore represents a promising approach to strengthening the body's own protection without inducing the psychoactive side effects of direct receptor activation by exogenous cannabinoids.

• Modulation of inflammatory responses via the activation of CB2 receptors on immune cells.
• Neuroprotective properties in acute injuries of the central nervous system.
• Influence on pain processing through attenuation of nociception in the spinal cord.
• Involvement in the regulation of appetite and overall energy balance in the hypothalamus.

Swiss context: Medical cannabis and road traffic

In Switzerland, research into the endocannabinoid system and active substances that act like 2-AG has gained importance following the legislative amendment in August 2022. Since then, medical cannabis can be prescribed by doctors without an exceptional permit from the BAG. Swiss physicians are increasingly using this option to treat chronic pain or spasticity. The prescribed phytocannabinoids, such as THC, mimic the effects of the body's own 2-AG on CB1 and CB2 receptors. Swissmedic monitors the quality of the approved preparations to ensure a standardised therapy that directly intervenes in these complex endogenous regulatory circuits.

However, therapeutic use poses legal challenges in everyday life, particularly in road traffic. Since exogenous cannabinoids occupy the same receptors as endothelial 2-AG but are metabolised much more slowly, fitness to drive is often impaired over the longer term. In Switzerland, a strict zero-tolerance policy applies with a statutory THC limit of 1.5 micrograms per litre of blood. Patients must be aware of this strict regulation, as the detection of THC in the blood leads directly to the revocation of the driving licence, regardless of subjective fitness to drive or therapeutic benefit.

• Facilitated access to cannabinoid-based therapies in Switzerland since August 2022.
• Interaction of medical phytocannabinoids with natural 2-AG receptors.
• Strict Swiss zero-tolerance limit of 1.5 micrograms of THC per litre of blood in road traffic.
• Quality assurance and monitoring of medical cannabis by the regulatory authority Swissmedic.

Synthesis and degradation pathways as pharmacological targets

The precisely controlled life cycle of 2-AG is crucial for the temporal and spatial limitation of signal transmission in the nervous system. Synthesis occurs on demand from membrane lipids by the enzyme diacylglycerol lipase, or DAGL, as soon as a strong influx of calcium into the postsynaptic cell takes place. Unlike classical neurotransmitters, 2-AG is not stored in vesicles but is released immediately after production. This on-demand synthesis ensures that the endocannabinoid system only becomes active when overstimulation of the synapses is imminent, protecting the neural network from functional overload.

The degradation of 2-AG occurs primarily through the enzyme monoacylglycerol lipase, known as MAGL, which cleaves the molecule into arachidonic acid and glycerol. Since arachidonic acid is a direct precursor for pro-inflammatory prostaglandins, the degradation pathway of 2-AG directly links the endocannabinoid system to inflammatory cascades. The pharmacological inhibition of MAGL is therefore an intensively researched field. By blocking this enzyme, the concentration of protective 2-AG in the tissue can be increased, while simultaneously reducing the production of pro-inflammatory substances, opening up new therapeutic avenues.

• On-demand synthesis by the enzyme diacylglycerol lipase upon calcium influx.
• Primary degradation by monoacylglycerol lipase to arachidonic acid and glycerol.
• Direct biochemical link between endocannabinoid degradation and inflammatory processes.
• Pharmacological MAGL inhibition as a therapeutic approach for pain and inflammation relief.

FAQ